Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer

• Published in: Cancer chemotherapy and pharmacology Vol. 83; no. 6; pp. 1183 - 1189
• Main Authors: Phillips, Roger M., Loadman, Paul M., Reddy, Guru
• Format: Journal Article
• Language: English
• Published: Berlin/Heidelberg Springer Berlin Heidelberg 01.06.2019; Springer Nature B.V
• Subjects: Antineoplastic Agents - administration & dosage; Antineoplastic Agents - pharmacokinetics; Antineoplastic Agents - pharmacology; Aziridines - administration & dosage; Aziridines - pharmacokinetics; Aziridines - pharmacology; Bladder cancer; Blood; Cancer; Cancer Research; Cell Line, Tumor; Chromatography, High Pressure Liquid; Clinical trials; Half-Life; Hematuria; Hematuria - complications; High-performance liquid chromatography; Humans; In Vitro Techniques; Indolequinones - administration & dosage; Indolequinones - pharmacokinetics; Indolequinones - pharmacology; Invasiveness; Medicine; Medicine & Public Health; Oncology; Pharmacology/Toxicology; Research Design; Short Communication; Statistical analysis; Urinary Bladder Neoplasms - drug therapy; Urine; Non-muscle invasive bladder cancer; Apaziquone; Haematuria

Purpose Despite positive responses in phase II clinical trials, the bioreductive prodrug apaziquone failed to achieve statistically significant activity in non-muscle invasive bladder cancer in phase III trials. Apaziquone was administered shortly after transurethral resection and here we test the h...